AR and prostate carcinoma: Our observation is of particular significance because it shows that WDL affects the viability of both androgen receptor-positive LNCaP (35), and androgen receptor-negative PC3 and DU145 (36,37) human prostate cancer cells with similar potency (IC50s of ∼8–12 μM), suggesting that this effect of WDL is independent of androgen receptor status of these cancer cells.